Table of Contents
Structure and Triple-Agonist Design
Retatrutide (also known in pharmaceutical development contexts as LY3437943) is a 39-amino acid acylated peptide. Its design incorporates structural elements from both native GLP-1 and GIP sequences, with modifications that confer activity at all three target receptors — GLP-1R, GIPR, and GCGR — while also providing resistance to enzymatic degradation and an extended half-life suitable for weekly dosing in clinical research contexts.
The acylation at a specific lysine residue in the peptide chain enables albumin binding, which is the primary mechanism for extending the compound's circulating half-life. This design approach is similar to that used in other long-acting GLP-1 analogues but is adapted here to balance agonist activity across three distinct receptor targets rather than one or two.
From a synthesis standpoint, the structural complexity of Retatrutide — the combination of a long amino acid sequence, a specific acylation pattern, and the requirement for precise regioselectivity — makes it one of the more analytically demanding peptides to characterize at the COA level. Researchers should ensure that any supplier provides MS confirmation of molecular weight alongside HPLC purity data.
The Three Target Receptors
Understanding Retatrutide's research context requires familiarity with its three receptor targets and their physiological roles:
GLP-1R (Glucagon-Like Peptide-1 Receptor): A class B G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and other tissues. In research models, GLP-1R activation is associated with glucose-dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and appetite signalling in hypothalamic circuits.
GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor): Also a class B GPCR, expressed in pancreatic islets, adipose tissue, bone, and the CNS. GIPR signalling is involved in insulin secretion, lipid metabolism, and bone metabolism in laboratory models.
GCGR (Glucagon Receptor): Another class B GPCR, primarily expressed in hepatic tissue. In research contexts, GCGR activation increases hepatic glucose output and is also associated with thermogenic and lipolytic signalling in adipose tissue.
The rationale for simultaneous triple-receptor engagement in Retatrutide's design is to leverage the metabolic effects of each receptor pathway while producing a net signalling profile that differs from single or dual agonist approaches. Researchers studying these receptor pathways should review the metabolic research category and related compounds including Tirzepatide for comparative pathway study designs.
Published Research Landscape
Retatrutide entered active clinical investigation relatively recently compared to earlier GLP-1R agonists, but has generated a rapidly growing body of published data. The primary literature includes preclinical pharmacology characterizing receptor binding affinities and selectivity across the three target receptors, rodent model studies examining metabolic and body composition endpoints, and published clinical trial data from Phase 1 and Phase 2 investigations.
Phase 2 clinical data, published in peer-reviewed journals, has documented Retatrutide's pharmacokinetic profile, dose-response characteristics, and observations across various metabolic endpoints under controlled clinical trial conditions. These publications provide researchers with reference data for receptor engagement patterns, circulating compound concentrations, and half-life parameters that can inform in vitro and ex vivo study design.
For researchers building literature foundations, PubMed searches combining "retatrutide," "LY3437943," "triple GLP-1 agonist," and "GIP GLP glucagon receptor" will locate the relevant primary literature. Phase 3 data continues to emerge as of early 2026.
Comparison to Related Incretin Compounds
Retatrutide sits within a family of incretin-based research peptides that includes single GLP-1R agonists, dual GLP-1R/GIPR agonists, and other GCGR-incorporating designs. For Canadian researchers considering compound selection for receptor pathway studies, the key distinctions are in receptor selectivity profile, half-life, and the available evidence base for each compound.
Tirzepatide, also available in the metabolic category, provides a dual GLP-1R/GIPR agonist reference point — its receptor binding and pharmacological profile are well-characterized in the published literature and serve as a useful comparison benchmark. Retatrutide extends this by adding GCGR engagement, introducing hepatic glucose output and thermogenic dimensions to the receptor pharmacology picture.
Researchers designing comparative studies should consider how the additional GCGR component affects downstream readouts in their specific model system, particularly in hepatocyte or adipocyte preparations where GCGR expression patterns differ from pancreatic cell lines.
Quality Considerations for Research Use
Given Retatrutide's structural complexity, quality documentation requirements are more demanding than for simpler linear peptides. A complete COA for research-grade Retatrutide should include:
- HPLC purity ≥98% — essential baseline for research-grade material
- Mass spectrometry confirmation — verifying the observed molecular weight matches the expected value for the acylated sequence; the acyl chain must be confirmed present, not assumed
- Lot number and testing date — confirming batch specificity of the documentation
- Peptide content data — particularly important for acylated peptides where TFA salt and water content can represent a meaningful fraction of total vial mass
The article on how to read a COA provides a comprehensive guide to evaluating each of these data points. The lab testing page explains the testing methodology applied to Peptides Canada products.
Sourcing Retatrutide in Canada
Retatrutide is available from Peptides Canada as Retatrutide 10mg, supplied for research and laboratory use with HPLC-verified purity. The compound ships from within Canada with appropriate cold-chain handling. Researchers can view current specifications and pricing on the product page.
For researchers with questions about documentation standards, comparative compound selection, or protocol considerations, the contact page is available for pre-purchase enquiries. The FAQ addresses common topics including storage, reconstitution, and order logistics. To browse all compounds in the metabolic research category alongside Retatrutide, visit the Metabolic collection.